Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of AEZS-108 vs standard single-agent chemotherapy in refractory triple-negative LHRH-R positive metastatic breast cancer
2012-000134-19Phase 2Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Jun 2012
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of zoptarelin doxorubicin in breast cancer (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoint: progression-free survival. Started Jun 2012; status: completed.
02
Drugs
zoptarelin doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000134-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000134-19.